Activaero inhales €10.7m in series A
This article was originally published in Clinica
Activaero, a German specialist in inhaled drug delivery technologies, has raised €10.7m ($15.8m) in its first round of venture financing. The series A round was led by BioMedPartners, and included VI Partners, Abalis Finance and Vesalius Biocapital I SICAR. The funds will go towards new product development and commercialisation. Gemünden-based Activaero's products – it currently has two on the market, the Akita and the Watchhaler – incorporate its controlled breathing technology that allows for more precise and patient-tailored delivery of inhaled therapeutics.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.